Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | PKM | P14618 | 2/20 | 0.84 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | GABRD | O14764 | 1/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.62 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10726712 | 1.00 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL10194850 | 0.92 | PKM (0.72) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL82433 | 0.92 | ALDH1A1 (0.72) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL6745615 | 0.92 | PKM (0.72) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL10192065 | 0.91 | ALDH1A1 (0.71) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL1753628 | 0.91 | HPGD (0.76) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL9410794 | 0.90 | ALDH1A1 (0.70) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL21915955 | 0.90 | PKM (0.70) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL12704671 | 0.90 | PKM (0.70) | ALDH1A1PKMHPGDMEN1KMT2A | |
| SCHEMBL20460439 | 0.90 | HPGD (0.80) | ALDH1A1PKMHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7514507-B2 | Comb-shaped epoxy resin and method for preparing comb-shaped epoxy resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20070142611-A1 | Comb-shaped epoxy resin and method for preparing comb-shaped epoxy resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-4031226-A | ANTIEMETIC, PSYCHOTROPIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | ALDH1A1 1556/4885PKM 2703/4885HPGD 3067/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | ALDH1A1 563/4885PKM 3828/4885HPGD 1342/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | ALDH1A1 591/4885PKM 3402/4885HPGD 1033/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885PKM 3543/4885HPGD 3255/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885PKM 3543/4885HPGD 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.